Roivant Sciences Management
Management criteria checks 4/4
Roivant Sciences' CEO is Matt Gline, appointed in Jan 2021, has a tenure of 3.92 years. total yearly compensation is $738.19K, comprised of 98.2% salary and 1.8% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth €292.85K. The average tenure of the management team and the board of directors is 3.9 years and 3.3 years respectively.
Key information
Matt Gline
Chief executive officer
US$738.2k
Total compensation
| CEO salary percentage | 98.2% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.004% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | US$738k | US$725k | US$4b |
| Dec 31 2023 | n/a | n/a | US$5b |
| Sep 30 2023 | n/a | n/a | -US$927m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | US$49m | US$725k | -US$1b |
| Dec 31 2022 | n/a | n/a | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | n/a | n/a | -US$1b |
| Mar 31 2022 | US$30m | US$725k | -US$845m |
| Dec 31 2021 | n/a | n/a | -US$1b |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$888m |
| Mar 31 2021 | US$8m | US$350k | -US$809m |
Compensation vs Market: Matt's total compensation ($USD738.19K) is below average for companies of similar size in the German market ($USD3.32M).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
CEO
Matt Gline (40 yo)
3.9yrs
Tenure
US$738,189
Compensation
Mr. Matthew Gline, also known as Matt, is Chief Executive Officer of Roivant Sciences Ltd. since January 26, 2021 and its Director since September 30, 2021. He has been Chief Executive Officer of Roivant S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | US$738.19k | 0.0037% € 292.8k | |
| President | 3.9yrs | US$574.56k | 0% € 0 | |
| Chief Financial Officer | 3.3yrs | US$5.15m | 0.021% € 1.7m | |
| Chief Accounting Officer | 6.3yrs | US$4.33m | 0.016% € 1.3m | |
| President & COO | 6.1yrs | US$48.49m | 0.039% € 3.1m | |
| Chief Information Officer | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Head of People | 2.9yrs | no data | no data | |
| Executive Vice President of Roivant Health | no data | no data | no data | |
| Chief Operating Officer of Roivant Platforms | no data | no data | no data | |
| Chief Development Officer | 2.6yrs | no data | no data | |
| Chief Scientific Officer of Dermavant | no data | no data | no data |
3.9yrs
Average Tenure
44yo
Average Age
Experienced Management: 87S's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.3yrs | US$738.19k | 0.0037% € 292.8k | |
| President | 1.1yrs | US$574.56k | 0% € 0 | |
| Independent Director | 1.8yrs | US$941.68k | 0.0018% € 142.8k | |
| Independent Director | 10.9yrs | US$442.59k | 0.17% € 13.9m | |
| Independent Director | 3.3yrs | US$459.24k | 0.011% € 851.3k | |
| Independent Director | 4.9yrs | US$449.24k | 0.88% € 70.9m | |
| Independent Director | 2.5yrs | US$444.24k | 0.0030% € 238.3k | |
| Independent Chairman | 10.9yrs | US$488.49k | 0.011% € 897.8k |
3.3yrs
Average Tenure
50yo
Average Age
Experienced Board: 87S's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 12:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Roivant Sciences Ltd. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |